JP2025510777A - 半減期が延長されたメッセンジャーリボ核酸 - Google Patents

半減期が延長されたメッセンジャーリボ核酸 Download PDF

Info

Publication number
JP2025510777A
JP2025510777A JP2024556411A JP2024556411A JP2025510777A JP 2025510777 A JP2025510777 A JP 2025510777A JP 2024556411 A JP2024556411 A JP 2024556411A JP 2024556411 A JP2024556411 A JP 2024556411A JP 2025510777 A JP2025510777 A JP 2025510777A
Authority
JP
Japan
Prior art keywords
seq
mrna
nucleic acid
utr
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510777A5 (enExample
Inventor
リード，デイビッド
アルバート ジマー，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of JP2025510777A publication Critical patent/JP2025510777A/ja
Publication of JP2025510777A5 publication Critical patent/JP2025510777A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024556411A 2022-03-25 2023-03-24 半減期が延長されたメッセンジャーリボ核酸 Pending JP2025510777A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263323748P 2022-03-25 2022-03-25
US63/323,748 2022-03-25
US202263405142P 2022-09-09 2022-09-09
US63/405,142 2022-09-09
US202263419924P 2022-10-27 2022-10-27
US63/419,924 2022-10-27
PCT/US2023/016192 WO2023183550A2 (en) 2022-03-25 2023-03-24 Messenger ribonucleic acids with extended half-life

Publications (2)

Publication Number Publication Date
JP2025510777A true JP2025510777A (ja) 2025-04-15
JP2025510777A5 JP2025510777A5 (enExample) 2026-03-31

Family

ID=86330236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556411A Pending JP2025510777A (ja) 2022-03-25 2023-03-24 半減期が延長されたメッセンジャーリボ核酸

Country Status (6)

Country Link
US (1) US20250313830A1 (enExample)
EP (1) EP4499850A2 (enExample)
JP (1) JP2025510777A (enExample)
CN (1) CN119234042A (enExample)
TW (1) TW202345870A (enExample)
WO (1) WO2023183550A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118542697B (zh) * 2024-05-13 2025-07-08 广州万方健医药有限公司 性生活使用后的避孕套在同时采集和/或检测男性和女性生殖道病原体中的应用
WO2026085234A1 (en) * 2024-10-18 2026-04-23 Modernatx, Inc. 3' untranslated region sequences for extending messenger ribonucleic acids half-life

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CA3174553A1 (en) * 2020-03-05 2021-09-10 Flagship Pioneering Innovations Vi, Llc Host defense suppressing methods and compositions for modulating a genome
EP4158005A1 (en) * 2020-06-01 2023-04-05 ModernaTX, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2021248008A1 (en) * 2020-06-05 2021-12-09 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
EP4168556A2 (en) * 2020-06-23 2023-04-26 ModernaTX, Inc. Lnp compositions comprising mrna therapeutics with extended half-life

Also Published As

Publication number Publication date
TW202345870A (zh) 2023-12-01
US20250313830A1 (en) 2025-10-09
EP4499850A2 (en) 2025-02-05
WO2023183550A3 (en) 2023-11-09
CN119234042A (zh) 2024-12-31
WO2023183550A2 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
EP3852728B1 (en) Preparation of lipid nanoparticles and methods of administration thereof
EP3917503B1 (en) Methods of preparing lipid nanoparticles
JP2025108727A (ja) 脂質ナノ粒子の生成方法
KR20220133957A (ko) 지질 나노입자의 제조 방법
US20230242908A1 (en) Lnp compositions comprising mrna therapeutics with extended half-life
WO2018089540A1 (en) Stabilized formulations of lipid nanoparticles
TW202313967A (zh) Ｒｎａ疫苗
JP2021504335A (ja) フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド
JP2023527875A (ja) フェニルアラニンヒドロキシラーゼバリアント及びその使用
JP2025510777A (ja) 半減期が延長されたメッセンジャーリボ核酸
JP2025507571A (ja) チェックポイントがんワクチンをコードするｍＲＮＡ及びその使用
CN118946365A (zh) 编码检查点癌症疫苗的mRNA及其用途
WO2023009499A1 (en) Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a)

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260323